Roche's surging diagnostics arm scored a major win this week, gaining FDA approval what is being billed as the first companion diagnostic meant to detect a specific mutation connected to metastatic non-small cell lung cancer.
Qiagen has purchased Ingenuity Systems for $105 million in cash. The Netherlands-based buyer plans to integrate the genomic database and analysis software from Ingenuity into its molecular diagnostics business. The buyout highlights the growing value of understanding the nuances of genomics to make precise diagnoses.
Dutch diagnostics giant Qiagen grabbed Ingenuity Systems in a $105 million cash deal, giving it new technology to boost the analysis of genomic data for molecular diagnostics.
Eli Lilly is expanding its partnership with Qiagen, building off of past success in a new broad collaboration agreement for companion diagnostics.
Qiagen disclosed it is seeking the FDA's blessing for a lung cancer-drug companion diagnostic, a test designed to screen patients for whom Boehringer Ingelheim's investigational treatment might work.
Diagnostics outfit Qiagen ticked its revenue up 5.3% in the third quarter, but acquisition gains from last year made for a 17% decline in net income in the period.
Qiagen has signed on with Bayer to develop companion diagnostics for Bayer's solid tumor treatments, using the company's QIAsymphony Dx platform.
Last month's FDA approval of Qiagen's diagnostic for the cancer drug Erbitux is indicatative of a trend in pharma: Drugmakers and regulators are recognizing the importance of companion diagnostics in the world of targeted treatments, The Financial Times reports.
The FDA has approved Qiagen's genetic biomarker-based therascreen KRAS RGQ PCR Kit. This can pick out the metastatic colon cancer patients who are most likely to respond to Erbitux (cetuximab), and this test will be launched by Bristol-Myers Squibb and Eli Lilly.
Qiagen is poised to cash in on the FDA's approval of Erbitux for colorectal cancer, as the agency also OK'd the Dutch firm's companion diagnostic for the top-selling cancer drug.